Podcast Summary

Podcast: That Can't Be True with Chelsea Clinton

Episode: Microdosing GLP-1s, Ozempic Babies & Obesity with Dr. Fatima Cody Stanford
Date: February 26, 2026
Guest: Dr. Fatima Cody Stanford (Obesity Medicine Physician & Scientist, Massachusetts General Hospital & Harvard Medical School)

Episode Overview

This episode delves into the surge in GLP-1 medications (like Ozempic and Wegovy), misconceptions around obesity, and the nuance behind the treatment of this complex, chronic disease. Public health expert and physician-scientist Dr. Fatima Cody Stanford joins Chelsea Clinton to discuss the science behind obesity, the role of GLP-1s, the harms of stigma and misinformation, and the importance of seeing beyond “just diet and exercise.” The duo also addresses public messaging around obesity, the ethics of prescribing for non-medical reasons, and common myths through a "fact or fiction" lightning round.

Key Discussion Points & Insights

1. Dr. Stanford’s Path to Obesity Medicine

• Personal Roots: Dr. Stanford shares her early exposure to obesity as a health issue during projects with Black church communities.
• Insight: She found that community-based lifestyle interventions had only short-lived impacts, leading her to question the prevailing "just eat less and exercise" approach.
• Aha Moment: Treating a highly committed patient who, despite every lifestyle modification, couldn’t lose weight convinced her that obesity must have deeper biological roots.
• Quote (Dr. Stanford, 04:30):

  “Despite all of these modifications, she really still struggled ... I realized this needed to be something beyond just what she was doing and had to be more biological in nature.”

2. Medical and Societal Stigma

• Public Messaging: The group critiques federal public health ads portraying obesity as purely individual failure, using stigmatizing terms like “fat” or “obese.”
• Ideal Messaging: Dr. Stanford advocates for inclusive messaging that validates both healthy behaviors and the need for medical or multidisciplinary care.
• Quote (Dr. Stanford, 08:36):

  “There was a lot of blaming and shaming ... this idea that it's as simple as just, ‘Oh, I can eat an apple and this will all go away.’”

3. The GLP-1 Surge: Hype and Misuse

• Clinical Background: GLP-1s have existed since early 2000s, first prescribed for diabetes, later for obesity. Their mainstream popularity blossomed c. 2021 after highly-effective once-weekly options like Ozempic/Wegovy emerged.

• Myth-Busting: Not a magic bullet. Severity of obesity should guide tool selection—lifestyle, medication, or surgery—mirroring how you would pick the right tool to clear a snowstorm.

• Microdosing Trend: Social media popularizes “microdosing” GLP-1s for vanity weight loss (e.g., losing 10-12 pounds quickly for events) without medical need or trials supporting safety/effectiveness.

• Population Concerns: Unknown population-level effects without evidence; concern over “doctors” prescribing off-label for profit, undermining principled care.

• Quote (Dr. Stanford, 15:04):

  “It would be the equivalent of me using lifestyle for someone with severe obesity.”

  Quote (Dr. Stanford, 16:15):

  “There are zero studies published ... for this idea of giving a small dose to maintain a certain image. That’s not the intended purpose of these medications.”

4. Complexity of Rising Obesity Rates

• Obesity: Not Just Food
  • Increased processed foods, but that's not the whole story.
  • Weight-promoting medications (antipsychotics, antidepressants, sleep drugs, diabetes meds, steroids) — many patients are surprised by this (24:17).
  • Societal sleep disruption (kids and adults sleep less and at odd hours vs. earlier generations).
  • Allostatic load (chronic stress, especially in marginalized communities) fosters weight gain.
  • Pandemic Paradox: Weight gain rose during COVID-19 despite more home cooking and exercise, due to stress.
  • Genetics play a key, often overlooked, role: offspring of parents with obesity much more likely to also deal with it.
• Quote (Dr. Stanford, 22:30):

  “Food is part of the problem, but ... there are a lot of things that have changed in the last 50 years ... when we add these things together can explain why we've seen this dramatic rise.”

5. Obesity as a Brain Disease & Mental Health Synergy

• Reframing the Conversation: Important to understand obesity as involving complex brain-gut interactions; treatment plans must include psychological/psychiatric care.
• Patient Example: A patient misunderstood “obesity as a disease” and felt “black and molded inside,” illustrating the need for sensitive, holistic care and communication (29:25).
• Quote (Chelsea Clinton, 30:40):

  “I could not imagine if I felt like there was mold in my body ... what a terrifying state to live in.”

6. Medical Cautions with GLP-1s

• Not for Everyone: Caution using GLP-1s in people with a history of disordered eating; need robust nutritional and mental health monitoring outside clinical trials.
• Side Effects: Rapid weight loss can sometimes go too far, especially with inadequate monitoring.
• Long-term Safety: Dr. Stanford is confident about the long-term safety of GLP-1s (20+ years of data), with caveats around newer combination therapies (34:00).

7. Fact or Fiction Lightning Round (35:51–41:24)

BMI

• Outdated? Fact. Dr. Stanford recommends waist-to-height ratio instead—BMI simplistically reduces weight to just height and weight, missing nuance.
• Quote (Dr. Stanford, 38:01):

  “Fact ... It should have never been used.”

Health at Every Size

• Can someone in a bigger body be healthy? Nuanced. Must look “under the hood”—health can’t be judged from size alone (38:39).

GLP-1s and Cancer

• Cancer Risk? Early studies indicate GLP-1s may reduce risk in multiple cancers; more research coming (39:20).

“Ozempic Babies”

• Can GLP-1s enhance fertility? Fact. These drugs can increase fertility, possibly by reducing inflammation and treating underlying issues such as PCOS—patients should be off them two months before trying to conceive (39:57).

Apple Cider Vinegar/Supplements

• Weight Loss? Fiction. No evidence supports sustained weight loss from these.

Never Too Old or Sick to Improve Health

• Fact. Lifestyle and health improvements are always possible, regardless of age, weight, or status.

Notable Quotes & Memorable Moments

• On stigmatizing ads (08:36):

  “The use of the word obese, which is a highly stigmatizing word ... the use of the word fat ... then a lot of the blaming and shaming of individuals that have this disease ... as simple as just, oh, I can eat an apple ... there was a lot of problems in this ad.”

• On patients who’ve “tried it all” (11:31):

  “Most of my patients ... have already tried the diet, they've already tried the exercise ... so by the time they make it to me ... if I were to say, you know what? I think you should just go and eat an apple ... that would be, you know, somewhat patronizing to them.”

• On the “holy grail” misconception (15:04):

  “I'm a major believer in using the right tool for the size of the problem.”

• On microdosing and off-label use (16:15):

  “There are zero studies published ... for this idea of giving a small dose to maintain a certain image.”

• On multiple causes of rising obesity (22:30):

  “Food is part of the problem, but ... when we add these things together can explain why we've seen this dramatic rise.”

Timestamps for Key Segments

• [03:25] — Dr. Stanford describes her early experiences and realization obesity goes beyond lifestyle.
• [08:02] — Discussion and critique of a public health ad featuring Mike Tyson.
• [12:14] — The rise of GLP-1s, their history, new popularity, and myths.
• [15:04] — Dr. Stanford explains “right tool for the size of the problem” and mismatch in treatment expectations.
• [16:15] — “Microdosing” explained and dangers of vanity GLP-1 use.
• [22:30] — Why obesity rates have changed: food, medications, sleep, stress, genetics.
• [29:25] — Importance of psychology: patient story about misunderstanding “disease” language.
• [31:57] — Concerns about GLP-1s, disordered eating, and monitoring outside of trials.
• [33:45] — GLP-1 safety/long-term use.
• [35:51–41:24] — Fact or fiction lightning round.

Conclusion

This episode provides a nuanced, evidence-based breakdown of obesity as a complex disease, the appropriate and inappropriate uses of powerful new GLP-1 drugs, and the societal missteps in how we discuss, diagnose, and treat weight issues. Dr. Stanford is clear: Obesity requires multifactorial analysis and care, not blame; the data—not hype—should drive both treatment and public conversation.

Follow-Up:
Find Dr. Fatima Cody Stanford on Instagram: @AskDrFatima
For more: listen to previous and future episodes of "That Can't Be True."

Summary by: Podcast Summarizer AI (2024)